TargeGen was a private biopharmaceutical company based in San Diego, United States. The company specialized in the development of highly potent and selective small molecule kinase inhibitors targeting hematological malignancies and blood disorders. Their lead candidate was being developed for treating myeloproliferative diseases such as myelofibrosis and polycythemia vera. In 2010, Sanofi acquired TargeGen for $638M USD. Sanofi agreed to acquire TargeGen for $638M
Hematological malignancy
CTI LSF I
Syndicate
Observer
May 1, 2007
TargeGen acquired by Sanofi for $638M USD
Series D
TargeGen's lead asset was being developed for myelofibrosis and polycythemia vera, conditions without approved therapies at the time
